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ABSTRACT 
 
PREDICTING RESPONSE TO ANTI-PD-1 IMMUNOTHERAPY IN 
METASTATIC MELANOMA  
 
James W. Smithy,1 Lauren M. Moore,1 Kim Blenman,2 Vasiliki Pelekanou,1 Jamaal 
Rehman,1 Patricia Gaule,1 Pok Fai Wong,1 Veronique M. Neumeister,1 Katerina Politi,1 
Harriet M. Kluger,3 David L. Rimm1,3 
 
1. Department of Pathology, Yale School of Medicine, New Haven, CT 
2. Department of Dermatology, Yale School of Medicine, New Haven, CT 
3. Section of Medical Oncology, Yale School of Medicine, New Haven, CT 
 
 
Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a 
major unmet need in metastatic melanoma. Thus, we evaluated three alternative tissue- 
and blood based markers biomarkers for response to anti-PD-1 therapy. First, pre-
treatment melanoma samples were assayed for expression of: 1) IRF-1, a PD-L1 
transcription factor, as a proxy for a tumor’s capacity to express PD-L1, and 2) an 
immune activation panel consisting of CD3, Ki67, and Granzyme B to distinguish 
immune-active and immune-quiescent tumors. Additionally, we conducted pilot studies 
to determine the feasibility of measuring soluble PD-L1 in the plasma of cancer patients. 
For tissue-based assays, samples from melanoma patients that received 
nivolumab, pembrolizumab, or combination ipilimumab/nivolumab at Yale New Haven 
Hospital from May 2013 to March 2016 were collected. Expression of IRF-1 and PD-L1 
in archival pre-treatment formalin-fixed, paraffin-embedded tumor samples were 
assessed by the AQUA method of quantitative immunofluorescence. Objective 
radiographic response (ORR) and progression-free survival (PFS) were assessed using 
modified RECIST v1.1 criteria. For pilot studies of sPD-L1, plasma from 62 patients with 
   
non-small cell lung cancer and 10 cancer-free controls were accessed from pre-existing 
de-identified tissue banks at Yale School of Medicine. 
Nuclear IRF-1 expression was higher in patients with partial or complete response 
(PR/CR) than in patients with stable or progressive disease (SD/PD) (p = 0.044).  There 
was an insignificant trend toward higher PD-L1 expression in patients with PR/CR (p = 
0.085). PFS was higher in the IRF-1-high group than the IRF-1-low group (p = 0.017), 
while PD-L1 expression had no effect on PFS (p = 0.83).  In a subset analysis, a strong 
association between IRF-1 and PFS is seen in patients treated with combination 
ipilimumab and nivolumab (p = 0.0051).  Higher CD3 infiltrates were more likely to be 
associated with PR/CR (p = 0.0067) and with improved PFS (p = 0.017). Conversely, 
higher expression of Granzyme B within CD3+ cells was associated with SD/PD (p = 
0.023) and a trend toward inferior PFS (p = 0.066). Soluble PD-L1 in human plasma was 
detected by ELISA, and was elevated in NSCLC cases compared to controls (p < 
0.0001). 
As a measure of PD-L1 expression capability, IRF-1 expression may be a more 
valuable predictive biomarker for anti-PD-1 therapy than PD-L1 itself. Additionally, 
patients with quiescent immune infiltrates may benefit more from anti-PD-1 therapy than 
those with immune-active tumors. The viability of plasma-based predictive biomarkers 
for immunotherapies warrants additional investigation.  
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Immune checkpoint blockade in metastatic melanoma 
 
Evasion of host immune responses has been described as a key survival 
mechanism in cancer.1 Therapeutic blockade of immune checkpoints has recently 
revolutionized the treatment of multiple advanced tumor types, perhaps most 
dramatically metastatic melanoma.  
The promise of this modality in melanoma was first demonstrated by targeting the 
prototypical immune checkpoint molecule, cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4). In brief, CTLA-4 acts as an inhibitory counterpoint to the co-stimulatory 
receptor CD28 in the priming of naive T cells.2 When a T cell expressing CTLA-4 
encounters antigen-presenting cells, CTLA-4 competes with CD28 for its ligands, CD80 
(B7-1) and CD86 (B7-2). Instead of triggering kinase cascades typical of T cell 
activation, CTLA-4 activation initiates an inhibitory downstream program mediated by 
phosphatases SHP2 and PP2A.3  Thus, the T cell is then unable to traffic to tumors and 
initiate an effective anti-tumor response. As CTLA-4 has a higher affinity for CD80 and 
CD86 than does CD28,4 an inhibited phenotype takes precedence when both co-receptors 
are present. 
The clinical relevance of this pathway was demonstrated in a 2010 landmark 
phase III trial of the CTLA-4 blocking antibody ipilimumab.5 This trial of 676 patients 
showed an objective tumor response rate of 10% of patients, and a 26% three-year 
survival rate in a patient population with previously dismal outcomes. So-called “durable 
responses” in a subset of patients have been a unique characteristic of immunotherapies, 
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representing a paradigm shift from cytotoxic chemotherapy and molecularly targeted 
therapies.  
The next iteration of immune checkpoint blockade came with the development of 
agents targeting the axis of programmed death-1 (PD-1) and its ligand, programmed 
death-ligand 1 (PD-L1). Like CTLA-4, PD-1 is also an inhibitory receptor expressed on 
T cells. However, it acts at a later step in the tumor immunity cycle—at the point at 
which primed T cells would exert their cytolytic effect against tumor cells. The ligand 
PD-L1 is expressed on tumors as well as on antigen-presenting cells and lymphocytes in 
the tumor microenvironment,6 and upon binding to PD-1, can convert cytotoxic T cells to 
an anergic or apoptotic state.7 It can also reduce proliferation of T cells8 and convert TH1 
cells to a Treg phenotype.9 In non-neoplastic contexts, this mechanism is used 
physiologically in pregnancy to promote fetomaternal tolerance in placenta,10 and to 
protect surrounding tissue from an immune response against chronic infections.11  
Nivolumab and pembrolizumab are two monoclonal antibodies against PD-1, and 
were first investigated as monotherapies across a number of tumor types.12 Given the 
promising response rates in melanoma, larger-scale trials were quickly initiated for this 
indication. In the phase III CheckMate 066 trial, nivolumab showed an objective response 
rate of 40%, with a median progression-free response rate of 5.1 months.13 Grade 3 or 4 
adverse events were relatively infrequent, observed in 11.7% of patients. The response 
rate in this trial has been reproduced in other settings, with a response rate of 36.4% in a 
pooled analysis of four large trials for nivolumab monotherapy.14 Similar to ipilimumab, 
it appears that many of these responses are durable, with five-year survival rates from the 
earliest phase I trial recently reported as 34%.15 
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Results from the phase III melanoma trial of pembrolizumab monotherapy largely 
mirrored those of nivolumab. Patients in the arm receiving pembrolizumab injections 
every two weeks had a 33.7% objective response rate, with 13.3% of patients 
experiencing grade 3 or 4 toxicity.16 A recent meta-analysis showed a similar ORR of 
33% in 655 patients with a median overall survival of 23 months.17 While 14% patients 
experienced grade 3 or 4 adverse events, only 4% of patients stopped therapy because of 
toxicity.  
More recently, investigators have focused on combining PD-1 and CTLA-4 
blockade. The three-arm Checkpoint 067 trial compared the combination of ipilimumab 
and nivolumab against both nivolumab and ipilimumab monotherapies. Treatment 
response was 57.6% for combination therapy, compared to 43.7% for nivolumab 
monotherapy and 19.0% for ipilimumab monotherapy. Similarly, PFS was 11.5 months 
for the combination arm compared to 6.9 months with nivolumab and 2.9 months with 
ipilimumab. However, Grade 3-4 adverse events were observed in 54% of patients in the 
combination arm, compared to only 20% of those receiving ipilimumab alone.18 A recent 
pooled analysis of 1250 patients also showed higher ORR, longer PFS, and higher 
toxicity with combination compared to nivolumab monotherapy in both mucosal and 
cutaneous melanoma.19  
In an effort to reduce the immune toxicities with combined therapy, efforts are 
ongoing to study sequential treatment with nivolumab and ipilimumab. While few results 
have been published, it has been reported that response rate at 25 weeks with nivolumab 
followed by ipilimumab (41%) may be twice as high as in patients treated with the 
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reverse sequence (20%).20 These initial data will be helpful in the design of pending 
studies comparing sequential and concomitant therapy.  
 
PD-L1 as a predictive biomarker for anti-PD-1 immunotherapy 
In a majority of clinical trials for nivolumab and pembrolizumab, 
immunohistochemical assays for PD-L1 have been performed on paraffin-embedded pre-
treatment tumor samples in an effort to identify patients most likely to respond to these 
agents. In the phase III CheckMate 066 trial of nivolumab, the ORR was higher for 
patients with PD-L1 positive tumors (53% v. 33%).13 However, both PD-L1 positive and 
negative groups receiving nivolumab had a significant survival benefit compared to the 
control arm. Similarly, in the KEYNOTE-001 trial of pembrolizumab, PD-L1 positivity 
was associated with better PFS and better OS.21  
Despite these promising findings, the cumulative results of PD-L1 as a predictive 
biomarker have been mixed; many responses in PD-L1-negative tumors remain 
unexplained. Unlike in other cancer types (e.g., non-small cell lung cancer treated with 
pembrolizumab), there are no FDA-approved companion or complementary diagnostics 
based on PD-L1 for the treatment of melanoma. In a pooled analysis of four nivolumab 
trials including 440 melanoma patients, PD-L1 status did not affect objective response 
rates.14 Importantly, PD-L1 has not been shown to be an effective predictive biomarker 
for combination checkpoint blockade. In the CheckMate 069 trial of nivolumab and 
ipilimumab, PD-L1 expression was not associated with significantly higher ORR. 
Similarly, PD-L1 expression was not associated with higher PD-L1 expression in the 
combination arm of the CheckMate 067 study. Given the improved efficacy and 
increased frequency of immune-related toxicities with combination ipilimumab and 
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nivolumab, biomarkers for identifying the patients likely to respond to to this regimen 
remain a major unmet clinical need. 
There are multiple hypotheses that could explain the limited positive and negative 
predictive power of PD-L1 in this setting. Variability of semi-quantitative assays across 
trials is one of potential source of case mis-classification. In addition to using different 
sets of immunohistochemical reagents, trial sponsors empirically set different semi-
quantitative cutoffs to identify PD-L1 positive and PD-L1 negative cutoffs. For instance, 
in the phase III trial of nivolumab, PD-L1 positivity was defined as at least 5% tumor 
cells showing PD-L1 cell surface staining as determine by a pathologist.13 In contrast, the 
threshold for positivity was set as 1% in the phase III trial of pembrolizumab.16 
It is also possible that antibody binding is affected by post-translational 
modification of PD-L1, leading to false-negative or false-positive assay results. PD-L1 
has four potential N-linked extracellular glycosylation sites in its IgV-like and IgC-like 
domains.22 Antigen glycosylation has been shown to affect the binding of antibodies in 
other settings,23-25 and the epitopes of commercial antibodies are not publicly disclosed. 
Thus, it is possible that one or more of commercial antibodies target these glycosylated 
residues. As few data are available of the patterns of PD-L1 glycosylation in human 
tumors or their biological relevance, it may be important to assess the binding of several 
anti-PD-L1 antibodies to their antigen in both glycosylated and unglycosylated 
conditions.  
A better-documented explanation for PD-L1’s relatively poor performance as a 
predictive biomarker is its markedly heterogeneous staining pattern.26  In multiple tumor 
types, PD-L1 is often focally expressed in close proximity to lymphocytic infiltrates near 
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the tumor-stromal interface.27  In melanoma, PD-L1 expression correlates with higher 
CD8+ infiltrates across multiple anatomic sites.28 These observations have been further 
developed into a model of adaptive immune evasion, in which secretion of interferon 
gamma (IFNγ) by infiltrating immune cells locally activates JAK/STAT signaling in 
tumor cells and induces focal expression of PD-L1.29-32 In this context, it is possible that 
spatial or temporal sampling error could account for some of the yet-unexplained 
responses to anti-PD-1 therapy in PD-L1 negative tumors.  PD-L1 can also be 
constitutively expressed downstream of tumor-intrinsic oncogenic pathways; it remains 
unclear if the manner of PD-L1 induction confers differential susceptibility to checkpoint 
ability for response to immunotherapy. 
 
Interferon gamma signaling & IRF-1 as candidate predictive biomarkers 
 
Given the heterogeneity of PD-L1 expression, identifying a tumor’s capability to 
express PD-L1 under the appropriate inflammatory conditions might identify a broader 
range of cases able to respond to anti-PD-1 agents than assessment of PD-L1 alone. 
Specifically, we considered the expression of the PD-L1 transcription factor interferon 
regulatory factor-1 (IRF-1) as a possible marker for this capability.  IRF-1 lies 
immediately upstream of PD-L1 in the IFNγ-driven JAK/STAT signaling cascade,30 and 
has been shown to play a central role in regulating cancer cell’s response to IFNγ.33   
In brief, upon IFNγ binding, two transmembrane interferon gamma receptor 
heterodimers bind together into a four-peptide complex, which leads to the cross-
phosphorylation of associated intracellular Janus kinases (Jak) proteins on their tyrosine 
residues as well as phosphorylation of intracellular receptor subunits. This 
phosphorylated complex recruits cytoplasmic STAT proteins, such as STAT1, which are 
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in turn phosphorylated and converted into antiparallel dimers that can traffic into the 
nucleus. There, STAT1 binds to promoters of primary interferon response genes, which 
include IRF-1.29,34   
In addition to driving PD-L1 expression, IFNγ signaling has been previously 
implicated in antigen presentation and anti-tumor immune surveillance, including 
upregulation of both major histocompatibility complex I & II (MHC I & II).35 Early 
studies demonstrated that tumors lacking either the IFNγ receptor (IFNGR1) or STAT1 
grew faster in immunocompetent mouse hosts than tumors with intact JAK/STAT 
signaling.36 Similarly, murine tumors with dominant negative interferon gamma receptors 
also had a growth advantage.37 Interestingly, immunogenicity of IFNGR1 or STAT1 
deficient tumors could be restored with overexpression of TAP1, a processing enzyme 
that loads MHC I tetramers with peptide antigens.38 Taken together, these results could 
suggest that IFNγ-driven presentation of antigen is a critical step for immune surveillance 
of tumors. 
Perhaps unsurprisingly, IFNγ signaling has been implicated as important for 
responses to immune checkpoint blockade. Tumeh et al. reported higher phosphorylated 
STAT1 levels higher in both pre-treatment and on-treatment tumor samples from 
melanoma patients responding to PD-1 blockade than those that progressed on therapy.31 
However, immunohistochemical assays for phosphorylated antibodies in paraffin 
embedded tissue have historically not been highly reproducible. Further evidence has 
come from genomic analyses, including the identification of IFNγ related mRNA 
signatures in pretreatment associated with response to anti-PD-1 therapy.39 Also, acquired 
mutations in JAK1, JAK2, and the MHC I component beta-two-microglobulin were 
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found anecdotally in three patients who developed acquired resistance to pembrolizumab 
after initially responding to therapy.40 The same group of investigators recently extended 
this finding to primary resistance to PD-1 blockade. In a small clinical series, 1 of 9 
melanoma patients melanoma patients unresponsive to pembrolizumab carried 
homozygous mutations in JAK1, while 0 of 13 responders had homozygous mutations in 
any IFNγ signaling components or antigen presenting genes.41 
Unlike other components of the JAK/STAT pathway, IRF-1 is generated de novo 
in response to IFNγ binding, making it uniquely amenable to immunohistochemical 
assays. IRF-1 is encoded by a single gene on 5q31, and was identified in 1988 as the first 
of nine members of the IRF family of transcription factors. All members of this class 
have a conserved binding domain that recognizes interferon-stimulated response element 
sequences in the genome. IRF-1’s various roles were first characterized in immune cells. 
It is required for the development of neutrophils and macrophages, and can drive the 
development of a TH1 phenotype in CD4+ T cells.  Like NF-KB, IRF-1 has a role in 
innate immunity—it can stimulate secretion of pro-inflammatory cytokines downstream 
of pattern recognition receptors. Specifically, engagement of TLR9 causes IRF-1 to more 
efficiently migrate to the nucleus, where it exerts its transcriptional control.42 
Roles for IRF-1 in cancer have also been identified. As a tumor suppressor gene, 
IRF-1 was shown to be necessary for DNA-damage associated growth arrest and 
apoptosis.42 Loss of one IRF-1 allele has been correlated with gastric and esophageal 
cancers, suggesting that a second-hit mutation may promote oncogenesis.43 In melanoma, 
IRF-1 can be induced in a subset of melanoma cell lines; those that were not inducible 
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had distinct mRNA profiles, with lower levels of mTOR and Wnt/beta catenin 
transcriptomic signatures.44 
IRF-1 is also necessary for constitutive and induced PD-L1 expression in 
cancer.30 While it is possible that IRF-1 expression correlates with that of PD-L1, 
detection of this transcription factor may represent a cell state that is capable of 
expression of PD-L1 when facilitated by local molecular microenvironment. For 
example, deubiquitination of PD-L1 by CSN5 has recently been shown to be an 
important post-translational regulatory process affecting PD-L1 protein levels.45  PD-L1 
is also regulated by other mechanisms, including signaling pathways mediated by 
PTEN,46,47 mTOR,48 and EGFR.49  
 
 
Immune activation as a candidate predictive biomarker 
 
As IFNγ signaling is initiated by the secretion of IFNγ by tumor-associated 
immune infiltrates, it is also worth considering whether these infiltrates themselves can 
be assayed to predict response to immunotherapy. Melanoma has long been known to be 
among the most immune-rich tumors—in the 1960s, the pathologist A.J. Cochran 
reported that 37% of a series of 165 melanomas had lymphoid aggregates at their 
periphery and that an additional 35% were associated with a mixture of lymphocytes and 
plasma cells.50 It was later reported that higher levels of tumor-infiltrating lymphocytes 
(TILs) in primary cutaneous melanomas in the vertical growth phase were associated 
with more favorable prognoses.51 
Preclinical studies of the PD-1/PD-L1 axis suggested that the CD8+ T cell 
population may have a role as a predictive biomarker for anti-PD-1 immunotherapy, as 
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CD8+ cells were required for PD-L1 expression, as well as the recruitment of inhibitory 
Treg cells, in a ectopic mouse model of melanoma.52  However, the association between 
CD8+ cells in pretreatment tissue samples and response has not been robust.  While 
Tumeh et al. demonstrated an association in melanoma between CD8+ cells at the tumor 
margin with response to pembrolizumab,31 Taube et al. reported no such association in a 
mixed cohort of renal cell carcinoma, melanoma, and NSCLC treated with nivolumab.  
Interestingly, the former study also reported an increase in immune activation with the 
start of therapy, as measured by immune cell expression of Ki67, a marker of 
proliferation, and cytolytic Granzyme B. 
As an extension of this finding, it is possible that interrogating the pre-treatment 
activation status of TILs—as measured by Ki67 and Granzyme B—in melanoma 
specimens could potentially identify patients most likely to respond to anti-PD-1 
checkpoint blockade. While a basal level of activation may be required for further 
immune response with PD-1 blockade, alternatively, tumors with the greatest levels of 




Soluble PD-L1 as a candidate predictive biomarker 
 
In addition to tissue-based biomarkers, liquid biomarkers from the peripheral 
blood are gaining traction in the practice of oncology. Liquid biomarkers can be assayed 
with routine blood draws, and can thus be collected at more frequent intervals than tissue 
biopsies to track tumor evolution and gauge response to treatment. Clinically, this 
approach has advanced most rapidly in the treatment of non-small cell lung cancer 
(NSCLC)—in June 2016, the first blood-based assay for EGFR mutations was approved 
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by the Food and Drug Administration. Early studies have shown that blood-based assays 
for genetic alterations in NSCLC provide complementary information to tissue biopies,53 
and that they may be more sensitive for resistance mutations such as EGFR T790M given 
the heterogeneity of tumor subclones.54 
Given the heterogeneous expression of PD-L1 protein, it is possible that a plasma-
based assay for soluble PD-L1 (sPD-L1) protein may provide a more integrated measure 
of expression across the tumor and various metastases. In 2007, a soluble form of the 
closely related immune marker CD80 was identified; this isoform was generated through 
alternative splicing and retained its ability to bind to its receptor, CD28.55 Soluble PD-L1 
detected by enzyme-linked immunosorbent assay (ELISA) was reported in metastatic 
renal cell carcinoma in 2011. In a study of 172 patients, sPD-L1 was higher in patients 
with T3 and T4 stage tumors and higher nuclear grade. sPD-L1 retained the PD-1 binding 
domain and was able to promote apoptosis in T cells, and a univariate survival analysis 
showed that a doubling of sPD-L1 led to an increased risk of death, though this did not 
remain significant in a multivariate survival model.56  
sPD-L1 was shown to vary with treatment response in a French study of 288 
patients with diffuse large B cell lymphoma (DLBCL).57  In pre-treatment samples, sPD-
L1 was higher in patients with DLBCL than in healthy controls, and higher levels were 
associated with poorer prognosis in patients treated with CHOP chemotherapy regimen.  
After treatment, levels decreased in patients that experienced a complete remission. This 
suggests that in addition to serving a prognostic role, sPD-L1 may be used longitudinally 
to assess treatment response to anti-PD-1 therapy. 
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Less data has been published on sPD-L1 in tumor types treated commonly treated 
with anti-PD-1 immunotherapy, such as NSCLC and melanoma. A Chinese study of 
NSCLC showed that sPD-L1 was higher in patients compared to healthy controls, and 
that levels were higher in patients with adenocarcinomas compared those with squamous 
cell carcinomas.58  It remains to be seen whether sPD-L1 could serve as a predictive 
biomarker for response to anti-PD-1 immunotherapy in either melanoma or NSCLC. 
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II. PURPOSE & SPECIFIC AIMS 
 
 
Given the limited predictive value of current clinical assays for PD-L1 protein 
expression, this study will evaluate alternative biomarkers to predict response to anti-PD-
1 immunotherapy. Specific aims are:  
 
1. To compare quantitative immunohistochemical assays for IRF-1 and PD-L1 
as predictive biomarkers for both objective radiographic response and 
progression-free survival in a retrospective cohort of melanoma patients treated 
with anti-PD-1 immunotherapy 
2. To evaluate a multiplex panel of immune activation (CD3, Ki67, & Granzyme 
B) as a predictive biomarker using the same melanoma cohort and outcome 
measures as in Aim 1.  
3. To evaluate a plasma-based assay for soluble PD-L1 protein in the plasma of 
patients with NSCLC and healthy controls. 
  




IRF-1 and PD-L1 induction in cell lines 
 Melanoma cell lines were grown to 80% confluency, serum-starved for 24 hours 
and then treated with IFNγ or control media for 24 hours. Cells were then fixed directly 
on chamber slides, lysed for Western blotting, or fixed with formulate to generate 
paraffin-embedded (FFPE) pellets. Cells grown on chamber slides were washed twice in 
1X phosphate-buffered saline (PBS) and then fixed in 4% paraformaldehyde (PFA) with 
88 mM sucrose. For FFPE cell pellets, five ten-centimeter plates grown to confluency 
were first rinsed with PBS, and fixed in a solution 4% PFA at 4° Celsius overnight. Cells 
were then resuspended and rinsed three times in PBS before being washed twice in 80% 
ethanol (EtOH). Cell pellets were spun at 12,000 RPM and embedded in 2.2% melted 
agarose in PBS. Agarose-embedded pellets were incubated in 70% EtOH overnight and 
then sequentially dehydrated with one-hour incubations of 90% EtOH and 100% EtOH, 
two one-hour xylene washes, and submerged in molten paraffin for two hours before 
embedding.  IRF-1 and PD-L1 induction in cell lines was performed by Lauren Moore. 
Cell pellets were generated by James Smithy. 
 
Antibody Validation   
Antibodies for IRF-1 (CST D5E4; #8478) and PD-L1 (Spring Bioscience SP142; 
#M4420) were validated59 by immunoblotting and immunofluorescent staining. Upon 
treatment with IFNγ, melanoma cell lines upregulated IRF-1 and PD-L1 as detected by 
Western Blot (Figure 1A) and immunofluorescence (Figure 1B). Immunofluorescent 
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staining for IRF-1 was limited to the nucleus, while PD-L1 expression was detected in 
the membrane and cytoplasm.  Progressively increasing expression of each marker seen 
with increased IFNγ stimulation was used to confirm specificity. Immunofluorescent 
staining and image analysis was performed by James Smithy. 
 
Western blot 
 Cells were lysed in ice-cold M-PER mammalian Protein Extraction Reagent 
(Thermo Scientific) supplemented with protease inhibitors. To determine protein 
concentration a Bradford assay was conducted using the Bio-Rad protein assay reagent 
(Bio-Rad,). Proteins (30 µg) were subjected to sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (GE 
Healthcare). The resulting blots were blocked for 1 hour at room temperature (RT) in 5% 
skimmed dry milk diluted in 1X Tris-buffered saline supplemented with Tween-20 
(TBST). Blots were incubated at 4ºC overnight in primary antibodies specific for PDL-1 
(Spring Bioscience Clone SP142; diluted 1:500) or IRF-1 (Cell Signaling Technology 
Clone D5E4; diluted 1:1000). Following incubation, blots were washed with 5% 
milk/TBST before incubation with a horseradish peroxidase, labeled goat anti-rabbit IgG 
(Santa Cruz Biotechnology Inc.; diluted 1:5000) at RT for 1 hour. Blots were washed 
with 5% milk/TBST and bands were visualized using electrochemiluminescence 
detection reagents (Thermo Scientific). Western blots were performed by James Smithy 
and Lauren Moore. 
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Case identification for melanoma cohort 
 
 Medical records and tissue samples were identified for melanoma patients with 
non-ocular primary tumors treated with pembrolizumab or nivolumab within the Yale-
New Haven Health system before April 1, 2016 under a protocol approved by Yale 
Human Investigations Committee. 51 cases with available pre-treatment tissue specimens 
were identified and selected by a board-certified pathologist. Of these, 47 had appropriate 
imaging available (e.g., CT, PET, and/or MRI) to determine response and PFS by 
objective criteria.  Of the 47 cases, 21 (45%) demonstrated a partial or complete 
response, including one case of pseudo-progression. Objective radiographic response 
(ORR) and PFS were determined by review of available CT or MRI scans using modified 
RECIST v1.1 criteria.60 To account for the possibility of pseudo-progression,61 
progression at first follow up scan needed to be confirmed with further progression at a 
second follow up scan to be classified as PD. Twenty-eight cases (60%) were treated with 
single-agent pembrolizumab or nivolumab and 19 cases (40%) were treated with 
combination ipilimumab and nivolumab.   Additional cohort characteristics are described 
in Table 1. The response rates in the monotherapy and dual therapy arms were 46% and 
42%, and the median PFS were 5.9 and 6.1 months, respectively. Case identification, 
abstraction of clinical data, and assessment of response was performed by James Smithy. 
Identification of appropriate samples for staining was performed by James Smithy and 
Vasiliki Pelekanou.  
 
  





Table 1. Clinical and pathologic characteristics for 47 metastatic melanoma 
cases with available pre-treatment tissue. 
  
     
  All patients IRF-1 High IRF-1 Low 
N  47 31 16 
Median age at 
diagnosis  
62 63 60 
Sex Male 24 14 10 Female 23 17 6 
Race 
White 44 30 14 
Black 2 0 2 
Hispanic 1 1 0 
Treatment 
Pembrolizumab 18 12 6 
Nivolumab 10 4 6 
Ipilimumab + 




Yes 16 11 5 
No 31 20 11 
Mutation status 
BRAF 16 11 5 
NRAS 6 5 1 
CKIT 2 2 0 
None detected 23 13 10 
Stage at 
diagnosis 
I 5 3 2 
II 8 5 3 
III 17 11 6 
IV 11 8 3 
Unknown 6 4 2 
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Quantitative immunofluorescence for single markers: IRF-1 & PD-L1  
 FFPE whole-tissue sections, tissue microarrays (TMAs) and cell pellets were 
processed and stained as previously described62. Briefly, sections were baked for 30 
minutes at 60° C and underwent two 20-minute washes in xylenes. Slides were 
rehydrated in two 1-minute washes in 100% EtOH followed by one wash in 70% EtOH 
and finally rinsed in streaming tap water for 5 minutes. Antigen retrieval was performed 
in sodium citrate buffer, pH 6, for 20 minutes at 97°C in a PT module (LabVision). 
Endogenous peroxidases were blocked by 30-minute incubation in 2.5% hydrogen 
peroxide in methanol. Subsequent steps were carried out on the LabVision 720 
Autostainer (Thermo-Scientific). Nonspecific antigens were blocked by a 30-minute 
incubation in 0.3% bovine serum albumin (BSA) in TBST. Slides were then incubated 
with the target primary antibody, as well as a cocktail of two mouse monoclonal 
antibodies against S100 (Clone 15E2E2, BioGenex) and HMB45 (Clone HMB45, 
Biogenex) each diluted at 1:100 to define the tumor compartment. IRF-1 was detected 
with rabbit monoclonal antibody clone D5E4 (Cell Signaling Technologies) at 0.6 ug/mL 
and PD-L1 was detected with rabbit monoclonal antibody SP-142 (Spring Biosciences) at 
0.08 ug/mL. 
 Primary antibodies were followed by incubation with Alexa 546–conjugated goat 
anti-mouse secondary antibody (Life Technologies) diluted 1:100 in rabbit EnVision 
reagent (Dako) for 1 hour. Signal was amplified with Cy5-Tyramide (Perkin Elmer) for 
10 minutes, and then nuclei were stained with DAPI in BSA-tween for 10 minutes. Slides 
were mounted with ProlongGold (Life Technologies). Two TBS-T and one TBS wash 
wash performed between each step after the primary antibody. 
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 For cells fixed on chamber slides, samples were washed twice in PBS after 
fixation and permeabilized with 0.25% Triton X-100 in PBS for 10 minutes. Cells were 
washed twice in PBS and blocked with 1% BSA in PBS for 1 hour at room temperature. 
Block was decanted off slides and the primary antibody cocktail as described above was 
applied. Subsequent steps were identical to the staining of FFPE tissue, except the DAPI 
stain was substituted for mounting Prolong Gold with DAPI (Life Technologies). One 
PBS-T and one PBS wash were performed between each step after the primary antibody. 
 Immunofluorescence was quantified using automated quantitative analysis 
(AQUA) on all fields of view containing tumor on each slide. Briefly, fluorescent images 
of DAPI, Cy3 (Alexa 546-S100/HMB45), and Cy5 (PD-L1 or IRF-1) for each field of 
view (FOV)were collected. Image analysis was carried out using the AQUAnalysis 
software (Genoptix), which generated an AQUA score for each compartment by dividing 
the sum of target pixel intensities by the area of the compartment in which the target is 
measured63. PD-L1 was measured in the S100/HMB45-positive tumor compartment and 
IRF-1 was measured within the DAPI-positive nuclear compartment within the tumor 
compartment. A total AQUA score was determined for each case by averaging scores 
from each 20X field of view. Immunofluorescent staining, image capture, and image 
analysis were performed by James Smithy 
 
Quantitative immunofluorescence for multiplex immune activation panel 
FFPE cases were stained for the immune activation panel as described above 
through blocking in BSA/TBST, using a modified multiplex protocol on the LabVision 
720 Autostainer (Thermo-Scientific) as previously described.64  Primary antibodies 
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against CD3, granzyme B, and Ki67 antibodies were coincubated for one hour at room 
temperature. CD3 was detected with rabbit monoclonal antibody SP7 at 1:100  
(Concentration unavailable, Novus Biologicals), Granzyme B was detected with mouse 
monoclonal antibody 4E6 (Abcam) at 500 ng/mL, and Ki67 was detected using mouse 
monoclonal MIB-1 (Dako) at  (460 ng/mL).  Slides were incubated sequentially with 
three horseradish peroxidase (HRP)–conjugated secondary antibodies for 1 hour at room 
temperature before tyramide-based HRP activation for 10 minutes, followed by 1 mmol/L 
benzoic hydrazide with 0.15% hydrogen peroxide to quench HRP activation. The 
secondary antibodies added sequentially were anti-rabbit Envision reagent (Dako), anti-
mouse IgG1 (Abcam; 1:100) to detect the MIB-1, and anti-mouse IgG2a (Abcam; 1:200) 
to detect 4E6 primary. After each secondary step, HRP activators were biotinylated 
tyramide (PerkinElmer; 1:50), TSATMPlus Fluorescein tyramide (PerkinElmer; 1:100), 
and Cy-5 tyramide (PerkinElmer; 1:50), respectively. Subsequently, slides were 
incubated in Alexa 750– conjugated streptavidin for 1 hour (1:100; Invitrogen). Two 
mouse monoclonal antibodies against S100 (Clone 15E2E2, BioGenex) and HMB45 
(Clone HMB45, Biogenex) and goat anti-mouse Alexa488 identified melanoma tumor 
compartment. DAPI identified nuclei. A schematic of this staining protocol is included in 
Figure 2. 
Quantitative analysis of all fields of view containing S100/HMB45-positive tumor 
was performed using inForm Advanced Image Analysis Software version 2.x (Perkin 
Elmer). A spectral library was prepared using single stains of the following dye or 
fluorochromes: DAPI, FITC, Cy3, Cy5, and Cy7. Each dye or fluorochrome was 
separated into a discrete channel. Vectra III .im3 image files were loaded into the 
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software. Fluorochromes and dyes in the Vectra III images were unmixed using the 
spectral library. The tissues in the images were segmented into tumor and stroma areas 
with the use of the automated tissue segmenter embedded in the software. In each of the 
areas, individual cells were segmented into nuclei, cytoplasm, and membrane using stains 
in the nucleus and membrane as internal and external cell borders. This allows for 
isolation of individual cells and quantitation of cells by staining patterns. Thresholds for 
positivity was set for each stain based on optical density--cell-based scores for each 
marker were thresholded as follows to binarize cell populations into positive and negative 
subgroups: CD3 (Cy7): 1.5; Granzyme B (Cy5): 4; Ki67 (Cy3): 12.   
 Immunofluorescent staining and image capture were performed by James Smithy. 
Image analysis on Inform was performed by Kim Blenman, and statistical analysis was 
performed by James Smithy.  
 
Chromogenic staining for IRF-1 & PD-L1 
 FFPE cases were stained for IRF-1 as described above through the secondary 
antibody incubation. Then, slides were incubated with 3,3'-diaminobenzidine peroxidase 
substrate (Vector Laboratories) for 8 minutes and counterstained with Tacha’s Auto 
Hematoxylin (Biocare Medical). Slides were then dehydrated in washes of 70% EtOH, 
100% EtOH, and xylenes before mounting. Single-plex chromogenic staining for PD-L1 
on a serial section was performed using the FDA-approved 22C3 assay on the DAKO 
Link 48 automated staining platform. Staining for IRF-1 was performed by James Smithy 
and staining for PD-L1 was performed by Veronique Neumeister and John McGuire. 
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PD-L1 deglycosylation 
Lysates were prepared as described above for the melanoma cell lines mel624 
(mel624 WT), mel624 transfected with overexpressed PD-L1 (Mel624 B7H1), and 
NSCLC cell lines H441, H820, and A549 treated with IFNγ (A549 + IFNγ). Lysates were 
diluted in PBS to generate 9 µg protein samples in 9 µL buffer. To each sample, 1 uL 
PNGase F denaturing buffer (New England Biolabs) was added and then samples were 
heated to 100°C for five minutes. Then, 1.25 µL 10% NP40 (New England Biolabs) and 
1.25 uL 500 mM sodium phosphate pH 7.5 (New England Biolabs) were added before 
samples were sealed and incubated at 37°C for 3.5 hours. 
Samples were then denatured for five minutes at 100°C with 10X LDS loading 
buffer (Thermo Fisher Scientific) and 10X reducing buffer (Thermo Fisher Scientific) 
before being loaded to SDS-PAGE gel. Western blots were performed as described above 
with the following three antibodies: E1L3N (Cell Signaling Technologies), E1J2J (Cell 
Signaling Technologies), and SP142 (Spring Biosciences). Deglycosylation and Western 
blots were performed by James Smithy.  
 
Case identification for soluble PD-L1 
 Plasma samples from fifteen patients with non-small cell lung cancer treated with 
anti-PD-1 immunotherapy were obtained from the repository of Dr. Abhijit Patel in the 
Section of Therapeutic Radiology. Two patients had samples collected at two time points, 
for a total of 17 samples. Of these, nine samples were pre-treatment, five were on 
treatment, and three were post-treatment. The study cohort had a median age of 59 
(range: 45-81) and was 40% male.  
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Plasma samples from 10 age- and sex-matched cancer-free controls undergoing 
unselected surgeries at Yale New Haven Hospital were collected from the Program for 
Applied Translational Research (PATR) biorepository within the Yale Section of 
Nephrology. The median age of control patients was 60 (range: 29-63) and 40% were 
male. To determine whether sPD-L1 is nonspecifically upregulated in inflammatory 
states, samples were analyzed at two time points for each control patient: pre-operatively 
as well as two-days postoperatively. 
A second cohort of 47 plasma samples from NSCLC patients with known PD-L1 
tumor status was obtained from the Thoracic Oncology tumor bank. Primary tumors from 
these patients had previously been assessed for PD-L1 staining by AQUA quantitative 
immunofluorescence.26 Clinical and pathologic characteristics of this cohort are described 
in Table 2. 
 
ELISA for soluble PD-L1  
 Human plasma samples were evaluated for soluble PD-L1 using Human B7-H1 
DuoSet ELISA Kit (R&D Systems).  Unless otherwise specified, reagents were included 
in the kit or in DuoSet ELISA Ancillary Reagent Kit 2 (R&D Systems). First, 96-well 
plates were incubated with 100 uL Capture Antibody at working concentration of 4 
ng/mL in PBS overnight at room temperature. Wells were then washed three times with 
Wash Buffer, completely aspirating any liquid after each wash. Plates were blocked by 
adding 300 uL 1% BSA in PBS to each well for 1 hour at room temperature.  At this 
point, and after each step before the addition of Substrate Solution, plates were washed 
three times as described above. Wells were incubated with 100 uL sample or standard in 
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triplicate and covered with an adhesive strip for two hours at room temperature. For 
antigen detection, plates were incubated for two hours with 100uL biotinylated detection 
antibody diluted in reagent diluent with 2% normal goat serum (Life Technologies). 
Streptavidin-HRP diluted 1:200 in 1% BSA/PBS was added to each well and incubated in 
the dark for 20 minutes. 100 uL Substrate Solution was added to each well and plates 
were incubated in the dark for 20 minutes. 50 uL Stop Solution was then added to each 
well, and plates were gently tapped to mix reagents.  
 Plates were then immediately read at 570 nm and 450 nm using a ELx800 plate 
reader (Biotek). Readings at 570 nm were subtracted from readings at 450 nm to correct 
for optical imperfections in the plate. 
 Estimation of sPD-L1 concentration in patient sample was made by comparing 
sample readings to those from standard curves. Standard curves were generated with a 
serial dilution of recombinant PD-L1 diluted in the plasma of the investigator, who has 
no known medical comorbidities.  ELISAs for sPD-L1 were performed by James Smithy.  
 
Statistics  
AQUA scores between responders (PR/CR) and non-responders (SD/PD) were 
compared using an unpaired t test; PFS and OS between groups were compared using the 
log-rank test. A Cox proportional hazards model was constructed with age, sex, race, 
mutational status, prior checkpoint blockade, and IRF-1 status. All univariate statistical 
analyses was performed using GraphPad Prism 7 (GraphPad Software), and multivariate 
analysis was performed with JMP 11 (SAS Institute).  All statistical analyses were 
performed by James Smithy 


































Table 2. Clinical and pathologic characteristics for 47 NSCLC cases with matched 
plasma and tumor samples. 
  
N   47 
Median Age (Range)   69 (39-83) 






















Large cell 2 
Other neuroendocrine 1 




IRF-1 as a prognostic biomarker in metastatic melanoma 
 
To identify IRF-1 expression patterns in melanoma tissue, two TMAs of 
unselected metastatic melanoma cases (YTMA 98 and YTMA 59) were stained for IRF-1 
(Figure 3A). Of 115 tumor cases on YTMA 59, 28 exhibited identifiable nuclear staining; 
average AQUA scores for these positive cases ranged from 204 to 723 (Figure 3B). We 
then sought to assess whether IRF-1 is a prognostic factor in melanoma irrespective of 
treatment. Cases from TMA 59 were stratified into IRF-1-high and IRF-1-low cohorts 
using an AQUA cutpoint of 204 based on the threshold for visual positivity. In this 
cohort, IRF-1 did not predict overall survival (OS) (Figure 3C) or disease-specific 
survival (Figure 3D).  
 
 
IRF-1 as a predictive biomarker for anti-PD-1 immunotherapy 
 
To assess IRF-1 as a predictive marker for response to PD-1 blockade, serial 
whole-tissue sections from 47 melanoma patients treated with anti-PD-1 immunotherapy 
were then stained for IRF-1 and PD-L1 in three batches. Batch-to-batch assay 
reproducibility was assessed by correlating scores from an index tissue microarray run 
with each batch (Figure 4). The median number of 20X fields of view per case was 64 for 
IRF-1 (range: 4 - 667), and 64 for PD-L1 (range: 7 - 764). There were trends toward 
higher expression of both markers in metastases compared to primary tumors, and in 
patients treated with prior checkpoint blockade compared to patients without prior 
treatment, though these differences did not reach statistical significance (Figure 5).  There 
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was also a trend toward higher IRF-1 and higher PD-L1 in BRAF-mutant tumors 
compared to tumors without a known driver mutation (Figure 6, p = 0.06 for both 
markers). PD-L1 was higher in NRAS mutated tumors than in tumors without a known 
driver mutation (Figure 6B, p = 0.0003). 
When classified by best ORR, AQUA scores for nuclear IRF-1 expression were 
higher in patients with PR/CR than in patients with SD/PD (p = 0.044, Figure 7A).  There 
was a trend toward higher PD-L1 expression in patients with PR/CR (p = 0.085, Figure 
7B), though this did not reach statistical significance. We then compared PFS from the 
start of therapy by IRF-1 expression level. PFS was related to ORR, but there was wide 
variability in PFS in the PR/CR and SD groups (Figure 8). Treated cases were then 
stratified into IRF-1-high and IRF-1-low cohorts using the lowest tertile as the IRF-1-low 
cohort (AQUA cutpoint = 194).  PFS from the start of therapy was significantly higher in 
the IRF-1-high group than the IRF-1-low group (p = 0.017, Figure 7C). There was a trend 
toward higher OS in the IRF-1 high group, though this did not reach statistical 
significance (p = 0.060). To determine if there was biologic significance to this cutpoint, 
we determined the limit of detection for IRF-1 by staining five serum-starved melanoma 
cell lines for IRF-1 and identifying the lowest AQUA score a FOV with positive nuclear 
staining.  Of five cell lines, only YUSOC had positive IRF-1 staining in the absence of 
IFN γ, and the lowest FOV AQUA score was for YUSOC was 171 (Figure 9).  When the 
cohort was stratified by this cutpoint, PFS was still higher in the IRF-1-high than the IRF-
1-low group (p = 0.0386, data not shown).  Similarly, cases were stratified into PD-L1-
high and PD-L1-low cohorts using a visual cutoff of 120.  There was no difference in 
PFS (p = 0.83, Figure 7D) or OS (p = 0.98) between these two cohorts. 
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PD-L1 expression correlated with IRF-1 expression with a Pearson’s correlation 
coefficient of 0.52 (Figure 10A, p = 0.0002).  However, within the PD-L1-low cohort, 
four cases were classified as IRF-1-high. An example of one of these cases with high 
IRF-1 and low PD-L1 is shown in 10B and C. Despite this small sample size, there was a 
trend toward better PFS in those patients compared to those classified as IRF-1-low, PD-
L1-low (p = 0.083).   
 When patients were grouped by therapy (PD-1 inhibitors alone versus the 
combination with CTLA-4 inhibitors), IRF-1 predicted longer PFS in the combination 
ipilimumab/nivolumab group (Figure 11A, p = 0.0051), but this difference did not reach 
statistical significance in patients treated with single-agent nivolumab or pembrolizumab 
(Figure 11B, p = 0.22). 
 In a Cox proportional hazards model for PFS, IRF-1-low status conferred a hazard 
ratio of 7.13 (95% Confidence Interval: 1.98 – 29.55, p = 0.0023) when accounting for 
age, race, sex, mutational status, and prior checkpoint blockade.  When this model was 
modified to include average tumor IRF-1 expression as a continuous variable, IRF-1 
remained an independent predictor of longer PFS (p = 0.0036).  
To determine if variable PD-L1 glycosylation partially accounted for case 
misclassification, three commercial antibodies were evaluated for their ability to bind 
glycosylated and deglycosylated forms of PD-L1 in an in vitro model.  For each of the 
untreated cell lines with positive PD-L1 expression, PD-L1 was detected by Western Blot 
as a broad band centered at 50 kilodaltons using three antibodies (Figure 12). In cell lines 
treated with PNGase F, this band was resolved to a single narrow band at approximately 
30 kD. Results across the three antibodies were identical, except PD-L1 was only 
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detected in its deglycosylated form by E1L3N A549 lung cancer cells treated with IFNγ. 
No bands were observed with the negative control mel624 WT. 
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Immune activation panel as a predictive biomarker in metastatic melanoma 
 
Of the 47 melanoma cases stained for IRF-1, 10 cases were lymph node 
metastases and excluded from evaluation of immune infiltrates. The remaining 37 cases 
were stained with a multiplex panel for CD3, Granzyme B, Ki67, DAPI, and 
S100/HMB45 tumor mask. Visually, tumors largely fell into one of three patterns: 
immune-poor (Low CD3; Figure 13A), immune-quiescent (High CD3, low Granzyme B, 
low Ki67; Figure 13B), or immune-active (High CD3, high Granzyme B, high Ki67; 
Figure 13C).  
For each case, individual cells were counted and classified as positive or negative 
for CD3, Granzyme B, and Ki67 using the Vectra imaging platform. The number of cells 
per tumor, including tumor and infiltrating cells, ranged from 14,274 to 2,646,294. A 
higher percentage of CD3+ cells (CD3+/all cells) was associated with NRAS mutation 
status (Figure 14A) and CR/PR compared to SD/PD (Figure 15A, p = 0.0067), and 
predicted longer PFS from the start of therapy (Figure 15B, p = 0.017) when stratified by 
the optimal cutpoint selected for maximal effect size. Conversely, a higher percentage of 
CD3+ cells double-positive for CD3+ and Granzyme B+ (CD3+ Granzyme B+ / CD3+) 
was associated with SD/PD (Figure 15C, p = 0.023) and a trend toward inferior PFS 
(Figure 15D, p = 0.066). A higher percentage of CD3+ cells double positive for Ki67 and 
CD3 was associated with CR/PR (Figure 15E, p = 0.046), but was associated with a trend 
toward worse PFS from the start of therapy (Figure 15F, p = 0.079). Fractions of 
Granzyme B+ and Ki67+ CD3 cells were not associated with melanoma mutation status. 
(Figure 14B, C). 
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The markers were then combined to a generate a survival analysis reflecting three 
cohorts: immune-poor, immune-quiescent, and immune-active. When immune-rich (i.e., 
tumors with high numbers of CD3+ cells) cases were stratified into immune-quiescent or 
immune-active tumors based on the fraction of Granzyme B-positive CD3+ cells, there 
was a trend toward greater PFS in immune-quiescent tumors compared to both immune-
poor and immune-active tumors (Figure 16A, p = 0.099). The same trend was observed 
when immune-active status was defined by high levels either Ki67 or Granzyme B 
positivity, though it did not reach statistical significance (Figure 16B, p = 0.23). 
These analyses were then repeated with compartment-based AQUA scores in 
place of cell counts. CD3 signal in the DAPI compartment was higher in patients with 
PR/CR compared to SD/PD, though this did not reach statistical significance; likewise, 
there was a trend toward greater PFS in the CD3-high group (Figure 17A, B).  A 
statistically insignificant association was observed between higher Granzyme B in the 
CD3+ compartment with SD/PD and inferior PFS (Figure 17 C, D). There was no 
appreciable difference in Ki67 signal in the CD3+ compartment between patients with 
PR/CR and those with SD/PD (Figure 17E); however, there was a trend toward improved 
PFS in the Ki-67 low group (Figure 17F).  
A three-cohort survival analysis was also performed using AQUA scores as 
described above. Using this platform, immune-active status was associated with 
improved PFS, though this trend did not reach statistical significance with either 
definition of immune-active tumors (Figure 18 A, B). 
Lastly, the correlation between cell counts as assessed with Vectra and AQUA 
scores was assessed for each of the three makers. The fraction of CD3+ cells positively 
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correlated with AQUA score for CD3 in the DAPI compartment (R2 = 0.50; Figure 19A). 
Likewise, the percentages of double-positive GB+ CD3+ and Ki67+ CD3+ cells 
correlated with their respective AQUA scores (R2 = 0.58 and R2 0.80, respectively; 
Figure 19 B, C) 
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Soluble PD-L1 in non-small cell lung cancer 
 
Optical density and known concentrations of recombinant sPD-L1 were fit with a 
four-parameter logistic (4-PL) model (R2 = 0.9986) to generate a standard curve (Figure 
20A). Plasma samples from patients with NSCLC had significantly elevated sPD-L1 
levels compared to pre-operative or post-operative age- and sex-matched controls 
undergoing non-oncologic surgical procedures (Figure 20B, p < 0.0001). Though sample 
size was limited, sPD-L1 was higher in samples from patients currently receiving anti-
PD-1 immunotherapy compared to pre-treatment samples (Figure 20C, p = 0.02). In a 
subset analysis of pre-treatment samples, there was a trend toward higher sPD-L1 in 
patients that responded to anti-PD-1 immunotherapy compared to those that did not. 
sPD-L1 was then assessed in plasma samples for 47 patients with known PD-L1 
tissue staining status. sPD-L1 levels did not correlate with either average or maximal 
(i.e., highest field-of-view) PD-L1 AQUA scores for primary tumors stained with the 
SP142 or E1L3N (Figure 21). Additionally, sPD-L1 levels did not vary with age, sex, 
smoking status, histology, node status, tumor stage, or recurrence after surgery (Figure 
22). 
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V. DISCUSSION 
 
IRF-1 as a predictive biomarker 
Biomarkers for predicting response to anti-PD-1 immunotherapy have been 
identified as a critical unmet need in the treatment of metastatic melanoma.65 PD-L1 has 
been shown to be promising in some studies21 but not others.  Here we show pilot data to 
suggest that capability to express PD-L1, as measured by nuclear IRF-1 expression, may 
be more valuable as a predictive marker than PD-L1 itself. 
While IRF-1’s role in regulating an inflamed melanoma phenotype has been 
previously characterized,33 this is the first report of IRF-1 as a predictive tissue biomarker 
to anti-PD-1 immunotherapy in melanoma. Though the improved clinical responses for 
tumors with higher IRF-1 expression could reflect these tumors’ ability to express PD-
L1, this finding is also consistent with recent studies that have linked IFNγ signaling with 
response to PD-139,66-68 blockade. Given the role of IRF-1 as a mediator of IFNγ, it is also 
possible that IRF-1 captures a broader set of tumors suppressing immune effector cells 
through mechanisms other than PD-L1.  
In addition to inducing PD-L1, IFNγ signaling plays a central role in inducing 
tumor immunogenicity through the expression of major histocompatibility complex I 
(MHC I).36,37 In the pre-PD-1 era, a small study of 15 melanoma patients showed a site-
specific upregulation of IRF-1 and antigen-presentation machinery in lesions responding 
to immunotherapies.69 Presentation of neoantigens through MHC I may be required for 
ongoing response to anti-PD-1 immunotherapy, as loss of the antigen-presenting beta-two 
microglobulin was recently associated with acquired resistance with one patient treated 
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with pembrolizumab.40 IRF-1-low tumors may have defects in antigen presentation, 
rendering tumors “invisible” the immune system and resistant to anti-PD-1 therapy 
regardless of PD-L1 expression. 
Lastly, tumor expression of IRF-1 could reflect the presence of necessary TH1 
immune infiltrates in tumors with intact JAK/STAT signaling machinery. In this model, 
the absence of IRF-1 may be a surrogate marker of an immune-exclusionary phenotype70 
in cells that retain their ability to respond to interferon-gamma. Correlations between 
IRF-1, tumor-infiltrating lymphocytes, and immune-exclusionary gene signatures could 
help elucidate this relationship. 
Though variable antibody binding to glycosylated and de-glycosylated PD-L1 
was considered as one possible explanation for PD-L1’s poor performance as a predictive 
biomarker, it appears unlikely to be a major driver of case misclassification. Treatment 
with PNGase F yielded narrow bands on Western blot near PD-L1’s expected molecular 
weight of 33 kilodaltons,22 so it is likely that N-linked glycosyl residues were effectively 
removed. As all three antibodies tested bound both glycosylated and deglycosylated 
forms, it is unlikely their respective epitopes are affected by glycosylation. This is 
particularly of interest for E1J2J, which is directed against an extracellular epitope---
E1L3N and SP142 are antibodies directed against the intracellular domain of PD-L1, 
which does not have any N-linked glycosylation sites.  
To further illustrate the clinical relevance of PD-L1 glycosylation, it would be 
informative to repeat this experiment with antibodies from the FDA-approved IHC assays 
for PD-L1.  Also, as the conditions for antigen binding are markedly different on a 
Western blot compared to FFPE tissue, it would also be useful to perform in situ 
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deglycosylation on tumor samples and compare the efficacy of several antibodies in this 
setting. However, initial attempts to deglycosylate proteins with PNGase F in FFPE did 
not yield reproducible results. Further optimization of this protocol would help to 
determine whether glycosylation status has an effect on the performance of a given IHC 
assay. 
There are a number of limitations to consider for this pilot biomarker study 
comparing IRF-1 and PD-L1.  Perhaps the most significant is the small samples size and 
the fact that the study is a single institutional, retrospective analysis.  Another potential 
issue is the selection of a cutpoint to distinguish high from low expressers for an assay 
that results in a continuous data set.  Here, we sought to bolster the lowest-tertile cutpoint 
by also using the limit of detection in unstimulated melanoma cell lines.  Using this 
alternate cutpoint, only three cases were re-classified from the low-IRF-1 to the high-
IRF-1 group, and the difference in PFS between IRF-1-high and IRF-1-low patients 
remained significant. Further development of IRF-1 as a predictive biomarker will 
require validation of an optimal, reproducibly defined, cutpoint on additional cohorts, as 
well as inclusion in prospective studies.  Also, as the study cohort included patients 
treated with both single-agent PD-1 and combination PD-1/CTLA-4 blockade, future 
studies should likely be limited to a more uniform treatment strategy.  
While the underlying mechanisms remain unclear, there are a number of 
biological explanations that could explain the association between IRF-1 expression and 
response to anti-PD-1 immunotherapy. With further validation, it is possible that an IHC-
based assay for IRF-1 could be readily transferred to the clinical setting.  The concept of 
a companion diagnostic tested based on capability to express the target of PD-1 axis 
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therapy may address some of the current assays deficiencies related to heterogeneity or 




Immune activation as a predictive biomarker 
 
In addition to IRF-1, a multiplex immune activation panel was also evaluated as a 
biomarker to predict response to anti-PD-1 immunotherapy. This panel has been 
previously shown to be predictive of response in a discovery cohort of treated NSCLC, 
but has yet to be applied to melanoma (Schalper et al., manuscript in review).  
Reassuringly, higher proportions of CD3+ cells were predictive of both ORR as 
well as PFS. This observation is aligned with previous reports of the importance of T cell 
infiltrates in the response to anti-PD-1 immunotherapy, and suggests that this assay 
effectively quantitates T cell infiltrates. Notably, as CD3 is a pan-T cell marker, it 
remains unknown whether response depends on pre-existing CD4+ or CD8+ infiltrates. 
Previous attempts to quantitate the CD8+ population have been largely limited by 
difficulty in accurately assessing signals that represent low fraction of total tumor area 
(i.e., < 5%). More granular assessment of immune cell populations infiltrating pre-
treatment and on-treatment tumor samples will likely provide more specific predictions 
of response and further insights into the mechanisms underlying tumor destruction after 
PD-1 blockade. 
In addition to overall CD3+ counts, this assay also provides insight into their 
functional status via colocalization of CD3 with Ki67 and Granymze B. Within the 
immune compartment, the ratio of double-positive Granzyme B+ CD3+ cells to CD3+ 
cells also predicted ORR, with lower levels of Granzyme B associated with greater 
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clinical benefit. This observation may reflect that a population of quiescent CD3+ cells is 
required for an active anti-tumor response with the release of PD-1-mediated inhibition. 
Conversely, in tumors with active immune infiltrates, (CD3-high, Granzyme B-high), 
blockade of PD-1 may not further potentiate immune response. If these immune-active 
tumors are indeed subjected to ongoing cytolytic activity, and yet are not adequately 
controlled by the host immune system, it is possible that these tumors have developed 
alternative mechanisms of resistance from cytotoxic components that warrant further 
investigation. For example, a recent analysis of genomic data from The Cancer Genome 
Atlas showed that cytolytic activity was associated with mutations in antigen-presenting 
machinery, including beta-2-microglobulin, HLA-A, HLA-B, and HLA-C.71  
Few comparable data are available on immune activation as a predictor of 
response—one small study 13 patients found mRNA levels of Granzyme A, but not 
Granzyme B, higher in pre-treatment tumor specimens of responders than non-
responders.72  
The role of CD3+ cell proliferation as measured by Ki67 remains unclear—a 
higher percentage of Ki67+ CD3 cells was associated with PR/CR, but also trended 
toward inferior PFS. While Ki67 may represent an activated T cells, it is also possible 
that dysfunctional T cells may proliferate. Multiplex staining with immune inhibitory 
receptors such as PD-1 may elucidate whether proliferating T cells are likely to be 
functional. 
A three-cohort survival analysis distinguishing immune-poor (CD3-low), 
immune-active (CD3-high, GB-high +/- Ki67-high) and immune-quiescent (CD3-high, 
GB-low +/- Ki67-low) was also performed to mirror the analysis performed by Schalper 
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and colleagues. On the Vectra platform, the results trended toward what had been 
observed in NSCLC—the immune-quiescent tumors had the best PFS. However, the 
analysis of 37 melanoma tumors did not reach statistical significance.  
This retrospective study was underpowered with only 37 cases, and it is possible 
that the inclusion of additional cases would further resolve survival differences between 
immune-poor, immune-active, and immune-quiescent tumors.  A formal power analysis 
was not performed as all available samples at Yale were used in for this study. This 
cohort also contained more heterogeneity than the NSCLC cohort under study—while the 
NSCLC cases were exclusively treated with single-agent anti-PD-1 therapy (e.g., 
nivolumab or pembrolizumab), a significant portion of the melanoma cohort was treated 
with combination therapy of ipilimumab and nivolumab. It is plausible, but speculative, 
that the blockade of CTLA-4 may alter the immune activation status of a given tumor and 
change its susceptibility to PD-1 blockade.  
Alternatively, melanomas may be less heterogeneous than NSCLC in the degree 
of immune infiltration, so it is more difficult to identify an immune-poor cohort of 
tumors. The three-cohort PFS analysis is contingent on the setting of two or three cut-
points to delineate the high- and low-expressing cohorts for each marker. In this study, as 
well as that of NSCLC, these limits were empirically. It is possible that the selected 
cutpoints do not reflect meaningful differences in underlying tumor biology. Further 
validation of this assay would require prospectively selected cut-points, based either on 
biologic rationales or on these initial observations  
Capturing the same slides with both the AQUA and Vectra quantitative 
immunohistochemistry systems afforded an opportunity to compare these two imaging 
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platforms.  While AQUA calculates scores based on the cumulative signal intensity of a 
given target in a pre-specified mask (e.g., all CD3+ areas), the inForm software for 
Vectra leverages a user-trained machine learning algorithm to segment individual cells 
and phenotype them as positive or negative for each marker of interest.  These techniques 
represent fundamentally different ways of quantifying immunoflurorescent signal—while 
AQUA provides an objective target score, its accuracy has historically been limited when 
the mask area takes up a low percentage (i.e., less than 2-5%) of a field of view. In 
contrast, the Vectra platform relies on user input to define cell and tissue compartments. 
While this has raised concerns as to its run-to-run reproducibility, early studies have 
suggested that it may be better suited for detecting low-frequency events. This feature 
could be useful in characterizing immune infiltrates, which often take up a relatively 
small fraction of tumor area. The previous study of the activation panel assay in NSCLC 
by Schalper et al. solely leveraged the AQUA platform.  
Univariate analyses of CD3 infiltrates and Granzyme B positivity in CD3+ cells 
were more predictive when captured on the Vectra than on AQUA. Of the three markers, 
the correlation between AQUA and Vectra was also the poorest for CD3+ (R2 = 0.50). 
This suggests that cell counting may be a more viable method that compartment-based 
quantification for characterizing immune infiltrates. In future studies, is possible that 
Vectra may be able to overcome the limitations of low signal area and more accurately 
evaluate rare populations of infiltrating immune cells. 
In sum, while the combined three-cohort immune activation assay of CD3, Ki67, 
and Granzyme B did not predict PFS as previously observed in NSCLC, there was a 
similar trend toward better survival in the immune-quiescent panel when assessed by the 
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Vectra imaging system. Furthermore, the individual markers of CD3+ cell fraction and 
Granzyme B+ CD3+ / CD3+ cell fraction were associated with meaningful differences in 
ORR and PFS. The evaluation of more treated melanoma cases with this technique will 






Pilot studies of sPD-L1 in NSCLC 
 
In addition to comparing tissue-based markers, a pilot study was completed 
toward developing a clinically applicable plasma-based assay for soluble PD-L1.  Due to 
the unavailability of plasma from metastatic melanoma patients, plasma sPD-L1 levels in 
NSCLC patients were compared to those of age- and smoking-matched controls using a 
commercially available non-clinical PD-L1 ELISA kit. The tightly fitted standard control 
curve with known quantities of recombinant sPD-L1 in control plasma suggests that the 
optical signal from this assay accurately reflects sPD-L1 levels. Furthermore, initial 
analyses confirmed prior reports that sPD-L1 levels are elevated in NSCLC compared to 
cancer-free controls.58 As sPD-L1 levels were largely undetectable in cancer free both 
pre-operatively and two days after general surgery, it appears that sPD-L1 is not elevated 
in this nonspecific inflammatory state. Further testing of other inflammatory conditions, 
including autoimmune disease, is warranted to determine if sPD-L1 is specific to 
oncologic diagnoses. 
Initial results comparing sPD-L1’s relationship to anti-PD-1 therapy are 
provocative, but extremely limited by small sample size. Namely, a subset analysis 
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demonstrated sPD-L1 may be higher in on-treatment samples compared to pre-treatment 
samples, and that there was an insignificant trend toward higher expression in pre-
treatment samples of responders compared to non-responders.  Future studies in NSCLC 
and melanoma should draw from larger cohorts of pre-treatment and on-treatment 
plasmas samples, so that sPD-L1 can be thoroughly evaluated as a means to predict 
response to treatment and track response to therapy over time in responders and non-
responders. Ideally, plasma from clinical trial patients could be accessed for the best-
controlled evaluation of clinical endpoints.  
 Given these promising initial results, the ELISA technique evaluated could likely 
be applied to larger cohorts of patients treated with anti-PD-1 therapy to generate 
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